Drug Trial Radar · NCT07184632
A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity
Last checked: Nov 20, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
224
Actual
Start
Oct 1, 2025
Primary completion
Dec 14, 2026
Study completion Dec 14, 2026
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Sep 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study tests how well different doses of the medicine NNC0662-0419 help people living with overweight or obesity. The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating people living with overweight or obesity. There are 2 study treatments in this study, participants will get either NNC0662-0419, the treatment being tested or placebo, a treatment that has no active medicine in it. NNC0662-0419 is a new medicine which cannot be pre-scribed by doctors but has previously been tested in humans.
Conditions
- Overweight
- Obesity
Interventions
NNC0662-0419Drug
NNC0662-0419 will be administered subcutaneously.
PlaceboDrug
Placebo matched to NNC0662-0419 will be administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of treatment-emergent adverse events (TEAE)Time frame: From baseline (week 0) to end of study (up to week 44)
- Part B: Relative change in body weightTime frame: From baseline (week 0) to end of treatment (week 36)
- Part C: Occurrence of premature treatment discontinuation (Yes/No)Time frame: At end of treatment (week 24)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Celerion, Phoenix
Tempe, Arizona
Celerion, Lincoln
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.